IP Library › Granted Patent US 12,318,453
Granted Patent B2
US 12,318,453 · App. 18/386,101 · Granted Jun 3, 2025

Compositions and methods for increasing efficiency of cardiac metabolism

Inventor: Andrew D. Levin (Newton, MA)
Assignee: IMBRIA PHARMACEUTICALS, INC.
A61K47/551A61K31/495A61K47/55A61K47/60C07D401/12A61P3/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,318,453
App. No.
18/386,101
Granted
Jun 3, 2025
Kind
B2
Abstract

Compositions and methods for increasing efficiency of cardiac metabolism are provided.

Claims (5)

1. A method of treating ischemia in a subject suffering from ischemia, the method comprising providing to the subject a compound represented by formula (X):

2. The method of claim 1 , wherein the compound is provided as a pharmaceutical composition.

3. The method of claim 2 , wherein the pharmaceutical composition is provided to the subject orally.

4. The method of claim 3 , wherein the pharmaceutical composition comprises a format selected from the group consisting of a tablet, troche, lozenge, fast-melt, aqueous suspension, oily suspension, dispersible powder, granule, emulsion, hard capsule, soft capsule, syrup, and elixir.

5. The method of claim 1 , wherein the compound is provided to the subject at a dosage of from about 1 mg/kg/day to about 10 mg/kg/day.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 13, 2023
From: LEVIN, ANDREW
To: RA CAPITAL MANAGEMENT, LLC
Reel/Frame 065536/0569 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 13, 2023
From: RA CAPITAL MANAGEMENT, LLC
To: CARNOT, LLC
Reel/Frame 065536/0709 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 13, 2023
From: CARNOT, LLC
To: IMBRIA PHARMACEUTICALS, INC.
Reel/Frame 065536/0743 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 13, 2023
From: CARNOT, LLC
To: IMBRIA PHARMACEUTICALS, INC.
Reel/Frame 065536/0755 →
Continuity (10)
Continuation 17828640 · May 31, 2022
Division 17074877 · Oct 20, 2020
Continuation 16722754 · Dec 20, 2019
Continuation 16011196 · Jun 18, 2018
Provisional Application 62647926 · Mar 26, 2018
Provisional Application 62637434 · Mar 2, 2018
Provisional Application 62710316 · Feb 16, 2018
Provisional Application 62524237 · Jun 23, 2017
Provisional Application 62522214 · Jun 20, 2017
Related Publication 20240100173A1 · Mar 28, 2024
References Cited (176)
US 4100285A · Murai et al. · 1978 [cited by applicant]
US 4166452A · Generales, Jr. · 1979 [cited by applicant]
US 4256108A · Theeuwes · 1981 [cited by applicant]
US 4265874A · Bonsen et al. · 1981 [cited by applicant]
US 4574156A · Morita et al. · 1986 [cited by applicant]
US 4845099A · Ruger et al. · 1989 [cited by applicant]
US 4876257A · Hajos et al. · 1989 [cited by applicant]
US 4885300A · Press et al. · 1989 [cited by applicant]
US 5077288A · Lavielle et al. · 1991 [cited by applicant]
US 5286728A · Ferrini · 1994 [cited by applicant]
US 5340809A · Gaudry et al. · 1994 [cited by applicant]
US 5380726A · Ferrini · 1995 [cited by applicant]
US 5384319A · Ferrini · 1995 [cited by applicant]
US 5397780A · Mizuno et al. · 1995 [cited by applicant]
US 5399557A · Mizuno et al. · 1995 [cited by applicant]
US 5401743A · Rendenbach-Mueller et al. · 1995 [cited by applicant]
US 5428038A · Chatterjee et al. · 1995 [cited by applicant]
US 5527800A · Goto et al. · 1996 [cited by applicant]
US 5591849A · Kato et al. · 1997 [cited by applicant]
US 5641779A · Halazy et al. · 1997 [cited by applicant]
US 5770735A · Emonds-Alt et al. · 1998 [cited by applicant]
US 5776937A · Gante et al. · 1998 [cited by applicant]
US 5849745A · Wierzbicki et al. · 1998 [cited by applicant]
US 5856326A · Anthony et al. · 1999 [cited by applicant]
US 5962448A · Mizuno et al. · 1999 [cited by applicant]
US 5977111A · Mizuno et al. · 1999 [cited by applicant]
US 6087346A · Glennon et al. · 2000 [cited by applicant]
US 6121267A · Glase et al. · 2000 [cited by applicant]
US 6200989B1 · De Cillis et al. · 2001 [cited by applicant]
US 6214841B1 · Jackson et al. · 2001 [cited by applicant]
US 6271223B1 · Mizuno et al. · 2001 [cited by applicant]
US 6331623B1 · Mizuno et al. · 2001 [cited by applicant]
US 6528529B1 · Brann et al. · 2003 [cited by applicant]
US 6562978B1 · Imamura et al. · 2003 [cited by applicant]
US 6693099B2 · Degenhardt et al. · 2004 [cited by applicant]
US 7638531B2 · Mutahi et al. · 2009 [cited by applicant]
US 7666866B2 · Franciskovich et al. · 2010 [cited by applicant]
US 7772251B2 · Sturzebecher et al. · 2010 [cited by applicant]
US 7968538B2 · Becker et al. · 2011 [cited by applicant]
US 8016783B2 · Pastore et al. · 2011 [cited by applicant]
US 8202901B2 · Lopaschuk et al. · 2012 [cited by applicant]
US 8461117B2 · Sufi et al. · 2013 [cited by applicant]
US 8569495B2 · Chassaing et al. · 2013 [cited by applicant]
US 8697661B2 · Kritikou · 2014 [cited by applicant]
US 9096538B2 · Nakamura et al. · 2015 [cited by applicant]
US 9120801B2 · Alisi et al. · 2015 [cited by applicant]
US 10167258B2 · Chuang et al. · 2019 [cited by applicant]
US 10556013B2 · Levin · 2020 [cited by applicant]
US 10918728B2 · Levin · 2021 [cited by applicant]
US 10953102B2 · Levin · 2021 [cited by applicant]
US 11376330B2 · Levin · 2022 [cited by applicant]
US 11844840B2 · Levin · 2023 [cited by examiner]
US 11969422B2 · Patel · 2024 [cited by examiner]
US 20030191182A1 · Lopaschuk et al. · 2003 [cited by applicant]
US 20030232877A1 · Sikorski et al. · 2003 [cited by applicant]
US 20040082564A1 · Arrhenius et al. · 2004 [cited by applicant]
US 20050004121A1 · Palani et al. · 2005 [cited by applicant]
US 20070004750A1 · Lorsbach et al. · 2007 [cited by applicant]
US 20080108618A1 · Brann et al. · 2008 [cited by applicant]
US 20080161400A1 · Virsik et al. · 2008 [cited by applicant]
US 20090012096A1 · Gu · 2009 [cited by examiner]
US 20090197891A1 · Lecanu et al. · 2009 [cited by applicant]
US 20090258064A1 · Newell et al. · 2009 [cited by applicant]
US 20100022530A1 · Schiemann et al. · 2010 [cited by applicant]
US 20110046370A1 · Sim et al. · 2011 [cited by applicant]
US 20110137362A1 · Foreman et al. · 2011 [cited by applicant]
US 20110212072A1 · Henkel et al. · 2011 [cited by applicant]
US 20120214818A1 · Dudley · 2012 [cited by applicant]
US 20160060530A1 · Archetti et al. · 2016 [cited by applicant]
US 20160346397A1 · Milne et al. · 2016 [cited by applicant]
US 20170008950A1 · Capon · 2017 [cited by applicant]
US 20170105414A1 · Nakano et al. · 2017 [cited by applicant]
US 20180360975A1 · Levin · 2018 [cited by applicant]
US 20190084917A1 · Savourey et al. · 2019 [cited by applicant]
US 20190216936A1 · Levin · 2019 [cited by applicant]
US 20200138963A1 · Levin · 2020 [cited by applicant]
US 20210353617A1 · Levin et al. · 2021 [cited by applicant]
US 20220249463A1 · Levin et al. · 2022 [cited by applicant]
CA 2170615A1 · 1995 [cited by applicant]
CA 2186010A1 · 1995 [cited by applicant]
CN 101747292B · 2011 [cited by applicant]
DE 2714996A1 · 1977 [cited by applicant]
EP 0144991A2 · 1985 [cited by applicant]
EP 0251141A1 · 1988 [cited by applicant]
EP 615855A1 · 1994 [cited by applicant]
EP 661266A1 · 1995 [cited by applicant]
EP 749967A1 · 1996 [cited by applicant]
EP 1634598A1 · 2006 [cited by applicant]
EP 1886994A1 · 2008 [cited by applicant]
EP 2727916A1 · 2014 [cited by applicant]
JP S57131777 · 1982 [cited by applicant]
JP 2000147773A · 2000 [cited by applicant]
JP 2006113343A · 2006 [cited by applicant]
JP 2015017236A · 2015 [cited by applicant]
RU 2377989 · 2010 [cited by applicant]
RU 2377989C2 · 2010 [cited by applicant]
WO 1995000165A1 · 1995 [cited by applicant]
WO 9626196A2 · 1996 [cited by applicant]
WO 9630054A1 · 1996 [cited by applicant]
WO 9630343A1 · 1996 [cited by applicant]
WO 9728141A1 · 1997 [cited by applicant]
WO 9746549A1 · 1997 [cited by applicant]
WO 9858638A1 · 1998 [cited by applicant]
WO 9950247A1 · 1999 [cited by applicant]
WO 2001005763A2 · 2001 [cited by applicant]
WO 2002058698A2 · 2002 [cited by applicant]
WO 2002064576A1 · 2002 [cited by applicant]
WO 2003006628A2 · 2003 [cited by applicant]
WO 2006027223A1 · 2006 [cited by applicant]
WO 2006117686A2 · 2006 [cited by applicant]
WO 2006133784A1 · 2006 [cited by applicant]
WO 2007075629A2 · 2007 [cited by applicant]
WO 2007096251A1 · 2007 [cited by applicant]
WO 2007116074A1 · 2007 [cited by applicant]
WO 2007116243A2 · 2007 [cited by applicant]
WO 2008109991A1 · 2008 [cited by applicant]
WO 2009015485A1 · 2009 [cited by applicant]
WO 2009058818A2 · 2009 [cited by applicant]
WO 2009066315A2 · 2009 [cited by applicant]
WO 2009156479A1 · 2009 [cited by applicant]
WO 2011032099A1 · 2011 [cited by applicant]
WO 2012049101A1 · 2012 [cited by applicant]
WO 2015018660A1 · 2015 [cited by applicant]
WO 2016005576A1 · 2016 [cited by applicant]
WO 2016107603A1 · 2016 [cited by applicant]
WO 2018236745A1 · 2018 [cited by applicant]
WO 2020081361A1 · 2020 [cited by applicant]
Abrahamsson, 1998, In vitro and in vivo erosion of two different hydrophilic gel matrix tablets, European Journal of Pharmaceuticals and Biopharmaceutics, 46:69-75. [cited by applicant]
Aswathy, 2018, Formulation and Evaluaton of Mucoadhesive Buccal Tablet of Antianginal Drug, IJPPR. Human Journals, 13(1):43-71. [cited by applicant]
Bhosle, 2006, Mutual Prodrug Concept: Fundamentals and Applications, Indian Journal of Pharmaceutical Sciences, May-Jun., pp. 286-294. [cited by applicant]
Cheng, 2006, Discovery of Potent and Orally Available Malonyl-CoA Decarboxylase Inhibitors as Cardioprotective Agents, J. Med. Chem. 49:4055-4058. [cited by applicant]
Cheng, 2006, Synthesis and structure-activity relationship of small-molecule malonyl coenzyme A decarboxylase inhibitors, J. Med. Chem. 49:1517-1525. [cited by applicant]
Das, 1995, Essential Fatty Acid Metabolism in Patients with Essential Hypertension, Diabetes Mellitus and Coronary Heart Disease, Prostaglandins Leukotrienes and Essential Fatty Acids, 52, 387-391. [cited by applicant]
Extended European Search Report issued in European Application No. 18821590.9, date of mailing: Oct. 5, 2020, 6 pages. [cited by applicant]
Extended European Search Report issued in European Application No. 19872680.4, date of mailing: Jun. 20, 2022, 7 pages. [cited by applicant]
Extended European Search Report issued in European Application No. 22169109.0, date of mailing: Aug. 30, 2022, 7 pages. [cited by applicant]
Fang, 2011, Therapeutic inhibition of fatty acid oxidation in reight ventricular hypertrophy, Journal of Molecular Medicine, Springer, Berlin, DE, 90(1):31-43. [cited by applicant]
Fang, 2011. Therapeutic inhibition of fatty acid oxidation in right ventricular hypertrophy: exploiting Randle's cycle, Journal of Molecular Medicine, 90:31-43. [cited by applicant]
Fillmore, 2014, Malonyl CoA: A Promising Target for the Treatment of Cardiac Disease, Int. Union of Biochem. and Mol. Biol., 66(3):139-146. [cited by applicant]
Fillmore, 2014, Mitochondrial fatty acid oxidation alterations in heart failure, ischemic heart disease and diabetic cardiomyopathy, Brit. J. Pharmacol. 171:2080-2090. [cited by applicant]
Folmes, 2005, Fatty Acid Oxidation Inhibitors in the Management of Chronic Complications of Atherosclerosis, Current Atherosclerosis Reports 2005, 7, 63-70. [cited by applicant]
Gallaher, 1993, Viscosity and Fermentability as Attributes of Dietary Fiber Responsible of the Hypocholesterolemic Effect in Hamsters, J Nutr., 123, pp. 244-252. [cited by applicant]
Gao, 2011, Echocardiography in Mice. Curr Protoc Mouse Biol, 1:71-83. [cited by applicant]
Gibbs, 1995, Cardiac efficiency, Cardiovasc. Res. 30:627-634. [cited by applicant]
Gustafsson, 1999, Characterisation of particle properties and compaction behaviour of hydroxypropyl methylcellulose with different degrees of methoxy/hydroxypropyl substitution, European Journal of Pharmaceutical Scienc… [cited by applicant]
Handbook of Pharmaceutical Excipients, 6th Ed, 2009, pp. 326-329. [cited by applicant]
International Search Report and Written Opinion issued in International Application No. PCT/US2020/034611, date of mailing: Oct. 14, 2020, 45 pages. [cited by applicant]
International Search Report and Written Opinion issued in International Application No. PCT/US2020/34608, date of mailing: Oct. 14, 2020, 28 pages. [cited by applicant]
International Search Report and Written Opinion issued in International Application No. PCT/US2020/34609, date of mailing: Oct. 14, 2020, 22 pages. [cited by applicant]
International Search Report and Written Opinion issued in International Application No. PCT/US2021/039303, date of mailing: Nov. 26, 2021, 19 pages. [cited by applicant]
International Search Report and Written Opinion mailed Nov. 5, 2018, for International Patent Application PCT/US2018/038067 with International filing date Jun. 18, 2018 (11 pages). [cited by applicant]
International Search Report issued in an International Application No. PCT/US2021/030450, date of mailing: Sep. 27, 2021, 9 pages. [cited by applicant]
Kantor, 2000, The Antianginal Drug Trimetazidine Shifts Cardiac Energy Metabolism From Fatty Acid Oxidation to Glucose Oxidation by Inhibiting Mitochondrial Long-Chain 3-Ketoacyl Coenzyme A Thiolase, Circulation Researc… [cited by applicant]
Kotreka, 2011, Gastroretentive Floating Drug-Delivery Systems: A Critical Review, Critical Reviews in Therapeutic Drug Carrier Systems, 28(1):47-99. [cited by applicant]
Leriche, 2012, Cleavable linkers in chemical biology, Bioorg. Med. Chem. 20:571-582. [cited by applicant]
Levy, 2014, Vasodilators in Acute Heart Failure: Review of the Latest Studies, Curr Emerg Hosp Med Rep, 2 (2):126-134. [cited by applicant]
Lopaschuk, 2010, Myocardial Fatty Acid Metabolism in Health and Disease, Phys. Rev. 90:207-258. [cited by applicant]
Maskova, 2020, Hypromellose—A traditional pharmaceutical excipient with modern applications in oral and oromucosal drug delivery, Journal of Controlled Release, 324:695-727. [cited by applicant]
Morin, 1998, Evidence for the existence of [3H]-trimetazidine binding sites involved in the regulation of the mitochondrial permeability transition pore, Brit. J. Pharmacol. 123: 1385-1394. [cited by applicant]
Narokha, 2014, Antioidant effect of nicotinic acid on experimental doxorubicin-induced chronic heart failure, Current Topics in Pharmacology, 18:105-111. [cited by applicant]
Non-Final Office Action issued in U.S. Appl. No. 16/722,691, date of mailing: Aug. 19, 2020, 12 pages. [cited by applicant]
Pubchem, CID 2223657, Jul. 15, 2005, pp. 1-14. [cited by applicant]
Pubchem, CID-57503849, Create Date: Aug. 8, 2012, 16 pages. [cited by applicant]
Reddy, 2006, Lipid Metabolism and Liver Inflammation. II. Fatty liver disease and fatty acid oxidation, Am J Physiol Gastrointest Liver Physiol, 290: G852-G858. [cited by applicant]
Sabbah, 2005, Metabolic Therapy for Heart Disease: Impact of Trimetazidine, Heart Failure Reviews, 10, 281-288. [cited by applicant]
Sannino, 2009, Biodegradable Cellulose-based Hydrogels: Design and Applications, Materials, 2:353-373. [cited by applicant]
Schipke, 1994, Cardiac efficiency, Basic Res. Cardiol. 89:207-40. [cited by applicant]
Spiekerkoetter, 2010, Mitochondrial fatty acid oxidation disorders: clinical presentation of long-chain fatty acid oxidation defects before and after newborn screening, J Inherit Metab Dis, 33:527-532. [cited by applicant]
Steggall, 2017, Targeting Metabolic Modulation and Mitochondrial Dysfunction in the Treatment of Heart Failure, Diseases, 5(14):1-18. [cited by applicant]
Tang, 2009, The Metabolic Approach in Patients with Heart Failure: Effects on Left Ventricle Remodeling, 15(8):850-856. [cited by applicant]
The Merck Manual List of Diseases https://merckmanuals.com/professional (accessed Jan. 17, 2020), 4 pages. [cited by applicant]
Trammell, 2016, Nicotinamide riboside is uniquely and orally bioavailable in mice and humans, Nat. Commun. 7:12948, 14 pages. [cited by applicant]
Visser, 2008, Measuring cardiac efficiency: is it clinically useful? Heart Metab. 39:3-4. [cited by applicant]
Yong-Hu Fang, 2011, Therapeutic inhibition of fatty acid oxidation in reight ventricular hypertrophy, Journal of Molecular Medicine, Springer, Berlin, DE, 90(1):31-43. [cited by applicant]
Yuasa, 1988, Pharmacological Studies on the Actions of Trimetazidine and Its Derivatives, The Journal of Kansai Medical University, vol. 40, Issue 1, pp. 89-116. [cited by applicant]
Zhou, 2012, Trimetazidine Protects against Smoking-Induced Left Ventricular Remodeling via Attenuating Oxidative Stress, Apoptosis, and Inflammation, PLOS One, 7:1-7. [cited by applicant]